Found: 43
Select item for more details and to access through your institution.
CARISEL Çalışmasının Bir Etkililik ve Güvenlilik Alt Grup Analizi.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2024, v. 13, p. 105
- By:
- Publication type:
- Article
DTG/3TC Sabit Doz Kombinasyonu (SDK), TAF Bazlı Rejim (TBR) ile Eş Etkilidir: 96-hafta TANGO Alt-grup Analizleri.
- Published in:
- Mediterranean Journal of Infection, Microbes & Antimicrobials, 2021, p. 93
- By:
- Publication type:
- Article
Cabotegravir + Rilpivirine Long-Acting: Overview of Injection Guidance, Injection Site Reactions, and Best Practices for Intramuscular Injection Administration.
- Published in:
- Open Forum Infectious Diseases, 2024, v. 11, n. 6, p. 1, doi. 10.1093/ofid/ofae282
- By:
- Publication type:
- Article
Cardiometabolic Parameters 3 Years After Switch to Dolutegravir/Lamivudine vs Maintenance of Tenofovir Alafenamide–Based Regimens.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 7, p. 1, doi. 10.1093/ofid/ofad359
- By:
- Publication type:
- Article
Sustained Virologic Suppression With Dolutegravir/Lamivudine in a Test-and-Treat Setting Through 48 Weeks.
- Published in:
- Open Forum Infectious Diseases, 2023, v. 10, n. 3, p. 1, doi. 10.1093/ofid/ofad101
- By:
- Publication type:
- Article
Evaluating Diversity in Randomized Clinical Trials of Dolutegravir-Based Antiretroviral Therapy Regimens: Pooled 48-Week Analyses by Race, Sex, and Regional Subgroups.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 8, p. 1, doi. 10.1093/ofid/ofac304
- By:
- Publication type:
- Article
Changes in Inflammatory and Atherogenesis Biomarkers With the 2-Drug Regimen Dolutegravir Plus Lamivudine in Antiretroviral Therapy–Experienced, Virologically Suppressed People With HIV-1: A Systematic Literature Review.
- Published in:
- Open Forum Infectious Diseases, 2022, v. 9, n. 4, p. 1, doi. 10.1093/ofid/ofac068
- By:
- Publication type:
- Article
341. Risk of Type 2 Diabetes Mellitus after Antiretroviral Therapy Initiation in Individuals Living with HIV in the United States.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S181, doi. 10.1093/ofid/ofz360.414
- By:
- Publication type:
- Article
319. SWORD 1 and 2: Switch from TDF Containing Regimen to DTG+RPV Maintains Bone Mineral Density and Decreases Bone Turnover Markers Over 148 Weeks.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S169, doi. 10.1093/ofid/ofz360.392
- By:
- Publication type:
- Article
2842. Durable Efficacy of Two-Drug Regimen (2DR) of Dolutegravir (DTG) plus Lamivudine (3TC) in Antiretroviral Treatment-Naïve Adults with HIV-1 Infection at 96 Weeks: Subgroup Analyses in the GEMINI Studies.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S67, doi. 10.1093/ofid/ofz359.147
- By:
- Publication type:
- Article
2484. Patient Reported Outcomes After Switching to a 2-Drug Regimen of Dolutegravir + Rilpivirine: Week 148 Results from the Sword-1 and Sword-2 Studies.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S861, doi. 10.1093/ofid/ofz360.2162
- By:
- Publication type:
- Article
978. Changes in BMI Associated with Antiretroviral Regimens in Treatment-Experienced, Virologically Suppressed Individuals Living with HIV.
- Published in:
- Open Forum Infectious Diseases, 2019, v. 6, p. S36, doi. 10.1093/ofid/ofz359.080
- By:
- Publication type:
- Article
Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort.
- Published in:
- Infectious Diseases & Therapy, 2023, v. 12, n. 12, p. 2807, doi. 10.1007/s40121-023-00890-2
- By:
- Publication type:
- Article
HIV Treatment with the Two-Drug Regimen Dolutegravir Plus Lamivudine in Real-world Clinical Practice: A Systematic Literature Review.
- Published in:
- Infectious Diseases & Therapy, 2021, v. 10, n. 4, p. 2051, doi. 10.1007/s40121-021-00522-7
- By:
- Publication type:
- Article
The Association Between HIV Disclosure Status and Perceived Barriers to Care Faced by Women Living with HIV in Latin America, China, Central/Eastern Europe, and Western Europe/Canada.
- Published in:
- AIDS Patient Care & STDs, 2016, v. 30, n. 9, p. 435, doi. 10.1089/apc.2016.0049
- By:
- Publication type:
- Article
An indirect comparison of 144-week efficacy, safety, and tolerability of dolutegravir plus lamivudine and second-generation integrase inhibitor–based, 3-drug, single-tablet regimens in therapy-naive people with HIV-1.
- Published in:
- AIDS Research & Therapy, 2023, v. 20, n. 1, p. 1, doi. 10.1186/s12981-023-00507-1
- By:
- Publication type:
- Article
Virologically suppressed switch to Dolutegravir/Lamivudine 2-Drug regimen versus switch to commonly prescribed 3-Drug regimens in the United States.
- Published in:
- AIDS Research & Therapy, 2024, v. 21, n. 1, p. 1, doi. 10.1186/s12981-024-00668-7
- By:
- Publication type:
- Article
Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care.
- Published in:
- HIV/AIDS - Research & Palliative Care, 2024, v. 16, p. 133, doi. 10.2147/HIV.S452130
- By:
- Publication type:
- Article
Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting.
- Published in:
- Antiviral Therapy, 2022, v. 27, n. 1, p. 1, doi. 10.1177/13596535211073235
- By:
- Publication type:
- Article
Assessing the Virologic Impact of Archived Resistance in the Dolutegravir/Lamivudine 2-Drug Regimen HIV-1 Switch Study TANGO through Week 144.
- Published in:
- Viruses (1999-4915), 2023, v. 15, n. 6, p. 1350, doi. 10.3390/v15061350
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Fixed-Dose 2-Drug Regimen vs Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Phase 3, Randomized, Noninferiority TANGO Study
- Published in:
- Clinical Infectious Diseases, 2020, v. 71, n. 8, p. 1920, doi. 10.1093/cid/ciz1243
- By:
- Publication type:
- Article
Asian participants' experience in phase 3/3b studies of long‐acting cabotegravir and rilpivirine: Efficacy, safety, pharmacokinetic, and virological outcomes through week 96.
- Published in:
- HIV Medicine, 2024, v. 25, n. 3, p. 381, doi. 10.1111/hiv.13588
- By:
- Publication type:
- Article
Pregnancy outcomes and pharmacokinetics in pregnant women living with HIV exposed to long‐acting cabotegravir and rilpivirine in clinical trials.
- Published in:
- HIV Medicine, 2023, v. 24, n. 5, p. 568, doi. 10.1111/hiv.13439
- By:
- Publication type:
- Article
Long-Acting Cabotegravir+Rilpivirine Injection Site Reactions: Pooled Week 96 Results.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 277
- By:
- Publication type:
- Article
Asian Phase 3/3b Experience With Long-Acting Cabotegravir and Rilpivirine: Efficacy, Safety, and Virologic Outcomes Through Week 96.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. 275
- By:
- Publication type:
- Article
Impact of treatment adherence on efficacy of DTG + 3TC and DTG + TDF/FTC: pooled week 144 analysis of the GEMINI-1 and GEMINI-2 clinical studies.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S302
- By:
- Publication type:
- Article
Week 48 metabolic health after switch to DTG/3TC vs CAR by baseline regimen (SALSA).
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S300
- By:
- Publication type:
- Article
High rates of virologic suppression with DTG/3TC in newly diagnosed adults with HIV-1 infection and baseline viral load >500,000 c/mL: 48-week subgroup analysis of the STAT study.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S295
- By:
- Publication type:
- Article
Switching to DTG/3TC Is non-inferior to continuing current antiretroviral regimen at week 48: SALSA subgroup analyses.
- Published in:
- Infection & Chemotherapy, 2022, v. 54, p. S298
- By:
- Publication type:
- Article
DTG+3TC vs DTG+TDF/FTC (GEMINI-1&-2): Confirmed Virologic Withdrawals Through Week 96.
- Published in:
- Infection & Chemotherapy, 2020, v. 52, p. S376
- By:
- Publication type:
- Article
Predictors of RSV LRTI Hospitalization in Infants Born at 33 to 35 Weeks Gestational Age: A Large Multinational Study (PONI).
- Published in:
- PLoS ONE, 2016, v. 11, n. 6, p. 1, doi. 10.1371/journal.pone.0157446
- By:
- Publication type:
- Article
Dual Therapy Treatment Strategies for the Management of Patients Infected with HIV: A Systematic Review of Current Evidence in ARV-Naive or ARV-Experienced, Virologically Suppressed Patients.
- Published in:
- PLoS ONE, 2016, v. 11, n. 2, p. 1, doi. 10.1371/journal.pone.0148231
- By:
- Publication type:
- Article
Antiretrovirals and Weight Change: Weighing the Evidence.
- Published in:
- Clinical Infectious Diseases, 2024, v. 79, n. 4, p. 999, doi. 10.1093/cid/ciae191
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to the 2-Drug Regimen Dolutegravir/Lamivudine Versus Continuing a 3- or 4-Drug Regimen for Maintaining Virologic Suppression in Adults Living With Human Immunodeficiency Virus 1 (HIV-1): Week 48 Results From the Phase 3, Noninferiority SALSA Randomized Trial
- Published in:
- Clinical Infectious Diseases, 2023, v. 76, n. 4, p. 720, doi. 10.1093/cid/ciac130
- By:
- Publication type:
- Article
Efficacy and Safety of Switching to Dolutegravir/Lamivudine Versus Continuing a Tenofovir Alafenamide–Based 3- or 4-Drug Regimen for Maintenance of Virologic Suppression in Adults Living With Human Immunodeficiency Virus Type 1: Results Through Week 144 From the Phase 3, Noninferiority TANGO Randomized Trial
- Published in:
- Clinical Infectious Diseases, 2022, v. 75, n. 6, p. 975, doi. 10.1093/cid/ciac036
- By:
- Publication type:
- Article
SOLAR 12-MONTH RESULTS: RANDOMIZED SWITCH TRIAL OF CAB+RPV LA VS ORAL B/FTC/TAF.
- Published in:
- Topics in Antiviral Medicine, 2023, v. 31, n. 2, p. 78
- By:
- Publication type:
- Article
Using Climate-HIV to describe real-world clinical outcomes for people living with HIV taking dolutegravir-based regimens.
- Published in:
- International Journal of STD & AIDS, 2021, v. 32, n. 12, p. 1165, doi. 10.1177/09564624211027099
- By:
- Publication type:
- Article
State of the Antiretroviral Therapy in Human Immunodeficiency Virus Drug Resistance: Surveillance and Regional Gaps.
- Published in:
- AIDS Reviews, 2018, v. 20, n. 1, p. 42, doi. 10.24875/AIDSRev.M18000019
- By:
- Publication type:
- Article
State of the Antiretroviral Therapy in Human Immunodeficiency Virus Drug Resistance: Science and Technology Knowledge Gap.
- Published in:
- AIDS Reviews, 2018, v. 20, n. 1, p. 26, doi. 10.24875/AIDSRev.M18000018
- By:
- Publication type:
- Article
Pharmacokinetic Enhancement in HIV Antiretroviral Therapy: A Comparison of Ritonavir and Cobicistat.
- Published in:
- AIDS Reviews, 2015, v. 17, n. 1, p. 37
- By:
- Publication type:
- Article
Practical dosing guidance for the management of clinician-administered injections of long-acting cabotegravir and rilpivirine.
- Published in:
- Therapeutic Advances in Infectious Disease, 2023, v. 10, p. 1, doi. 10.1177/20499361231214626
- By:
- Publication type:
- Article
Efficacy, Safety, and Pharmacokinetics by Body Mass Index Category in Phase 3/3b Long-Acting Cabotegravir Plus Rilpivirine Trials.
- Published in:
- Journal of Infectious Diseases, 2024, v. 230, n. 1, p. e34, doi. 10.1093/infdis/jiad580
- By:
- Publication type:
- Article
Maternal and foetal outcomes among 4118 women with HIV infection treated with lopinavir/ritonavir during pregnancy: analysis of population-based surveillance data from the national study of HIV in pregnancy and childhood in the United Kingdom and Ireland.
- Published in:
- 2016
- By:
- Publication type:
- journal article